Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Umeclidinium bromide and vilanterol trifenatate (Anoro Ellipta) is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
• The information was derived from 12 systematic reviews/meta-analyses.
• Monoclonal antibodies, except Dupilumab, did not significantly improve FEV1 compared to traditional agents like UMEC/VI, which had a high SUCRA ranking of 93.5%.
• Vilanterol/umeclidinium showed the highest exacerbation rate at 53.0%, suggesting it may be less effective than some other LABA/LAMA combinations in preventing moderate or severe exacerbations.
• Among LABA/LAMA combinations, vilanterol/umeclidinium demonstrated the highest efficacy in improving trough FEV1 but indicated some loss of efficacy over time; it performed best for SGRQ but lower for preventing exacerbations compared to formoterol/aclidinium.
• LAMA/LABA fixed-dose combinations including UMEC/VI are generally comparable in efficacy and safety concerning lung function, symptoms, health status, and exacerbations in moderate-to-severe COPD cases.
• UMEC/VI provided statistically significant improvements in FEV1 versus all dual therapy and monotherapy comparators with similar or better outcomes regarding SGRQ scores, TDI scores, rescue medication use rates, and overall exacerbation rates among symptomatic COPD patients.
• Once-daily LABA/LAMA fixed-dose combinations including UMEC/VI significantly improved lung function and quality of life over placebo among individuals with GOLD stage II or III COPD.